TGTX•benzinga•
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
Summary
TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga